PMID- 33825991
OWN - NLM
STAT- MEDLINE
DCOM- 20210920
LR  - 20240102
IS  - 1432-0843 (Electronic)
IS  - 0344-5704 (Linking)
VI  - 88
IP  - 1
DP  - 2021 Jul
TI  - Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes 
      of patients with pancreatic ductal adenocarcinoma.
PG  - 109-120
LID - 10.1007/s00280-021-04267-5 [doi]
AB  - PURPOSE: Recently, the number of patients with pancreatic ductal adenocarcinoma 
      (PDAC) who have received both neoadjuvant chemotherapy (NAC) and adjuvant 
      chemotherapy (AC) has been increasing. However, whether adverse events (AEs) 
      during AC influence the prognosis of patients with resected PDAC who do or do not 
      receive NAC remains uncertain. METHODS: Patients with PDAC who underwent a 
      pancreatectomy between 2011 and 2019 were divided into two groups: an upfront 
      surgery (UFS) group (n = 72), and an NAC group (n = 77). Patients who received AC 
      were then divided into two groups: an AE grade 0/1/2 group (AE-G-0/1/2) and an AE 
      grade 3/4 group (AE-G-3/4). The relationship between AEs and patient outcome and 
      predictors of AE-G-3/4 were investigated. RESULTS: AC was used in 54 and 65 
      patients in the UFS and NAC groups, respectively. In the NAC group, the relative 
      dose intensity (RDI) and AC completion rate as well as the overall survival rate 
      of patients with AE-G-3/4 (n = 15) during AC were significantly worse than those 
      of patients with AE-G-0/1/2 (n = 50). However, similar differences were not 
      observed in the UFS group. A multivariate analysis revealed that AE-G-3/4 during 
      NAC, AC agent (gemcitabine), an albumin level < 3.5 g/dL, and an estimated 
      glomerular filtration rate < 90 mL/min/1.73 m(2) before the initiation of AC were 
      independent predictors of AE-G-3/4 during AC. CONCLUSIONS: AE-G-3/4 during AC was 
      associated with a lower RDI and AC completion rate and a worse outcome among 
      patients with PDAC who had received NAC.
FAU - Mori, Shozo
AU  - Mori S
AUID- ORCID: 0000-0002-6289-0905
AD  - Department of Gastroenterological Surgery, Dokkyo Medical University, 880 
      Kitakobayashi, Mibu, Shimotsuga, Tochigi, 321-0293, Japan. 
      s-mori@dokkyomed.ac.jp.
FAU - Aoki, Taku
AU  - Aoki T
AD  - Department of Gastroenterological Surgery, Dokkyo Medical University, 880 
      Kitakobayashi, Mibu, Shimotsuga, Tochigi, 321-0293, Japan.
FAU - Sakuraoka, Yuhki
AU  - Sakuraoka Y
AD  - Department of Gastroenterological Surgery, Dokkyo Medical University, 880 
      Kitakobayashi, Mibu, Shimotsuga, Tochigi, 321-0293, Japan.
FAU - Shimizu, Takayuki
AU  - Shimizu T
AD  - Department of Gastroenterological Surgery, Dokkyo Medical University, 880 
      Kitakobayashi, Mibu, Shimotsuga, Tochigi, 321-0293, Japan.
FAU - Yamaguchi, Takamune
AU  - Yamaguchi T
AD  - Department of Gastroenterological Surgery, Dokkyo Medical University, 880 
      Kitakobayashi, Mibu, Shimotsuga, Tochigi, 321-0293, Japan.
FAU - Park, Kyung-Hwa
AU  - Park KH
AD  - Department of Gastroenterological Surgery, Dokkyo Medical University, 880 
      Kitakobayashi, Mibu, Shimotsuga, Tochigi, 321-0293, Japan.
FAU - Matsumoto, Takatsugu
AU  - Matsumoto T
AD  - Department of Gastroenterological Surgery, Dokkyo Medical University, 880 
      Kitakobayashi, Mibu, Shimotsuga, Tochigi, 321-0293, Japan.
FAU - Shiraki, Takayuki
AU  - Shiraki T
AD  - Department of Gastroenterological Surgery, Dokkyo Medical University, 880 
      Kitakobayashi, Mibu, Shimotsuga, Tochigi, 321-0293, Japan.
FAU - Iso, Yukihiro
AU  - Iso Y
AD  - Department of Gastroenterological Surgery, Dokkyo Medical University, 880 
      Kitakobayashi, Mibu, Shimotsuga, Tochigi, 321-0293, Japan.
FAU - Kubota, Keiichi
AU  - Kubota K
AD  - Department of Gastroenterological Surgery, Dokkyo Medical University, 880 
      Kitakobayashi, Mibu, Shimotsuga, Tochigi, 321-0293, Japan.
LA  - eng
PT  - Journal Article
DEP - 20210407
PL  - Germany
TA  - Cancer Chemother Pharmacol
JT  - Cancer chemotherapy and pharmacology
JID - 7806519
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 0 (Gemcitabine)
SB  - IM
MH  - Adenocarcinoma/*drug therapy
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antimetabolites, Antineoplastic/*therapeutic use
MH  - Carcinoma, Pancreatic Ductal/*drug therapy
MH  - Chemotherapy, Adjuvant/*adverse effects
MH  - Deoxycytidine/*analogs & derivatives/therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoadjuvant Therapy/*adverse effects
MH  - Pancreatectomy/methods
MH  - Pancreatic Neoplasms/*drug therapy
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Gemcitabine
OTO - NOTNLM
OT  - Adjuvant chemotherapy
OT  - Gemcitabine
OT  - Neoadjuvant chemotherapy
OT  - Pancreatic cancer
OT  - S-1
EDAT- 2021/04/08 06:00
MHDA- 2021/09/21 06:00
CRDT- 2021/04/07 12:30
PHST- 2020/12/14 00:00 [received]
PHST- 2021/03/22 00:00 [accepted]
PHST- 2021/04/08 06:00 [pubmed]
PHST- 2021/09/21 06:00 [medline]
PHST- 2021/04/07 12:30 [entrez]
AID - 10.1007/s00280-021-04267-5 [pii]
AID - 10.1007/s00280-021-04267-5 [doi]
PST - ppublish
SO  - Cancer Chemother Pharmacol. 2021 Jul;88(1):109-120. doi: 
      10.1007/s00280-021-04267-5. Epub 2021 Apr 7.